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Abstract
Background: Anxiety disorders and depression (emotional disorders) are highly prevalent mental disorders. Extensive empirical
evidence supports the efficacy of cognitive behavioral therapy (CBT) for the treatment of these disorders. However, there are
still some barriers related to their dissemination and implementation, which make it difficult for patients to receive these treatments,
especially in public health care settings where resources are limited. Recent advances in improving CBT dissemination encompass
different perspectives. One is the transdiagnostic approach, which offers treatment protocols that can be used for a range of
emotional disorders. Another approach is the use of the internet to reach a larger number of people who could benefit from CBT.
Objective: This study aimed to analyze the effectiveness and acceptability of a transdiagnostic internet-delivered protocol
(EmotionRegulation) with human and automated guidance in patients from public specialized mental health care settings.
Methods: A 2-armed randomized controlled trial (RCT) was conducted to compare the effectiveness of EmotionRegulation
with treatment as usual (TAU) in specialized mental health care. In all, 214 participants were randomly assigned to receive either
EmotionRegulation (n=106) or TAU (n=108). Measurement assessments were conducted at pre- and postintervention and at a
3-month follow-up.
Results: The results revealed the superiority of EmotionRegulation over TAU on measures of depression (d=0.41), anxiety
(d=0.35), and health-related quality of life (d=−0.45) at posttreatment, and these gains were maintained at the 3-month follow-up.
Furthermore, the results for expectations and opinions showed that EmotionRegulation was well accepted by participants.
Conclusions: EmotionRegulation was more effective than TAU for the treatment of emotional disorders in the Spanish public
mental health system. The implications of this RCT, limitations, and suggestions for future research are discussed.
Trial Registration: ClinicalTrials.gov NCT02345668; https://clinicaltrials.gov/ct2/show/NCT02345668
(J Med Internet Res 2020;22(7):e18220) doi: 10.2196/18220
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Introduction
Disorder-Specific Cognitive Behavioral Therapy for
Emotional Disorders
Anxiety and depressive disorders, also known as emotional
disorders (EDs) [1], have the highest prevalence rates among
psychological disorders [2,3], and are associated with substantial
costs [4,5] and disability [6,7]. In the past three decades,
research efforts to decrease the burden of these disorders have
led to the development and evaluation of cognitive behavioral
treatments in randomized controlled trials (RCTs) for each ED
(ie, disorder-specific protocols), such as depression [8,9] and
several anxiety disorders, including generalized anxiety disorder
(GAD) [10,11], panic disorder (PD) and agoraphobia (AG) [12],
social anxiety disorder (SAD) [13], and obsessive compulsive
disorder (OCD) [14].
Although there is a large body of evidence showing the efficacy
and effectiveness of disorder-specific cognitive behavioral
therapy (CBT), in the past 15 years, an increasing number of
researchers have agreed that there are some problems that hinder
the optimal deployment of these treatments. The main drawback
of disorder-specific treatments stems from the high comorbidity
rates observed among anxiety disorders and between anxiety
disorders and depressive disorders, with comorbidity estimates
for these disorders ranging between 40% and 80% [15,16].
Thus, because disorder-specific treatment protocols focus on
treating a specific diagnosis, the accompanying comorbid
disorders do not receive therapeutic attention [17,18]. This
problem becomes clearer when we take into account research
linking comorbidity to aspects such as greater severity [3],
increased chronicity rates [19], and a worse clinical course [20].
Another problem with disorder-specific treatments is that
subthreshold symptoms that do not meet diagnostic thresholds
for a particular disorder, but might be important to treat,
normally go untreated [17]. Similarly, these protocols do not
address diagnoses that do not fit any specific category, despite
their clinical relevance, that is, not otherwise specified (NOS)
anxiety and depressive disorders [15]. Finally, each
disorder-specific treatment requires the use of different
handbooks and protocols, which increases the economic costs
and the amount of training needed to gain the knowledge and
skills necessary to cover the array of anxiety and depressive
disorders [17].
Transdiagnostic Treatments for Anxiety and
Depression
Transdiagnostic treatments have emerged as an alternative to
the traditional disorder-specific approach that has dominated
CBT research for the past 30 years. Transdiagnostic treatments
have been developed and tested in several RCTs for anxiety
disorders [21-24] and anxiety and depressive disorders [25-27],
and their number continues to grow. Moreover, the efficacy and
effectiveness of transdiagnostic treatments have been shown in
different meta-analytic reviews, comparing them with different
control groups, such as waiting list, attention control, and
treatment as usual (TAU) [28-31], with pooled effect sizes
(Hedges g) in the medium to large range for overall measures
of anxiety (0.65-0.82) and depression (0.79-0.84). Moreover,
an additional meta-analysis reported equivalent effects of
transdiagnostic treatments (g=1.06) and disorder-specific
treatments (d=0.95) on anxiety outcomes [32]. However, these
meta-analyses include a number of mixed studies of different
orientations, such as theory-based transdiagnostic treatments
and tailored CBT. Therefore, these studies make it difficult to
determine the effectiveness of each orientation (eg, the
effectiveness of theory-based transdiagnostic treatments). The
effectiveness of transdiagnostic treatments has also been shown
in a meta-analysis by García-Escalera et al [33], with pooled
effect sizes of g=0.80 for anxiety and g=0.72 for depression.
Unlike the abovementioned meta-analyses, this study has the
particularity that it only included theory-based transdiagnostic
treatments. The main characteristic of theory-based
transdiagnostic treatments, also known as mechanistically
transdiagnostic treatments or transdiagnostic treatments based
on shared mechanisms [34], is that they are designed to address
the common psychopathological processes underlying anxiety
and depression. Among the mechanistically transdiagnostic
treatments for EDs, the Unified Protocol (UP) [35,36] stands
out as one of the most empirically supported transdiagnostic
protocols for anxiety and depression [23,37,38]. The UP is a
CBT transdiagnostic protocol developed to address the
underlying psychopathological processes that are common to
anxiety and depressive disorders, with a particular focus on
neuroticism, (low) extraversion, and emotion dysregulation,
which have been shown to play a key role in the onset and
maintenance of these disorders [39,40]. Thus, the main goal of
the UP is to teach patients strategies to regulate their emotions
in a more adaptive way through the following core treatment
modules: (1) present-focused emotional awareness, (2) cognitive
flexibility, (3) identification and prevention of emotional
avoidance patterns, (4) increasing awareness and tolerance to
emotion-elicited physical sensations, and (5) graded
(interoceptive and situational) exposure procedures. The overall
efficacy of the UP was first shown in an RCT where it was
compared with a waitlist control group [23] and, more recently,
in a larger RCT where it was compared with well-established
disorder-specific CBT protocols for anxiety disorders [37]. In
addition, some research shows the long-term effects of the UP
[41] and its ability to produce changes in the temperament
dimensions of behavioral inhibition (BI) and behavioral
activation (BA) [42]. BI and BA have been conceptualized as
2 neurological systems representing motivational tendencies
that are sensitive to threat and reward environmental cues,
respectively [43]. These aspects have been intimately linked to
neuroticism and negative affect and extraversion and positive
affect [42]. Another treatment approach that includes principles
or components that could be useful to target EDs is dialectical
behavioral therapy (DBT) [44,45]. DBT initially emerged as a
theoretical model and a treatment approach for the treatment of
suicidal behaviors and borderline personality disorder, with the
general aim of teaching strategies to change patterns of emotion
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dysregulation [46]. Of the range of strategies, DBT places a
special emphasis on increasing experiential awareness and
acceptance (mindfulness what and how techniques), but it also
includes behavioral strategies such as the opposite action,
designed to diminish distress by engaging in behaviors or actions
opposite to those associated with negative emotions [44]. More
recently, DBT skills have been adapted and successfully applied
to several anxiety and depressive disorders [47,48], which
suggests that they could be used in a transdiagnostic manner to
improve the symptomatology of these disorders. For example,
DBT principles may be combined with other evidence-based
components (eg, components of the UP) to strengthen their
effectiveness. The strategy of integrating CBT principles and
components from different evidence-based therapies and
orientations is consistent with the notion of process-based CBT,
defined by Hofmann and Hayes [49]. As the authors state,
“modern CBT places much less focus on protocols for
syndromes and more focus on evidence-based processes linked
to evidence-based procedures” [49].
Internet-Delivered Interventions
In the past two decades, one of the most evident efforts made
by researchers has been to take advantage of the possibilities
offered by information and communication technologies to
improve the assessment and treatment of psychological
disorders. A clear example would be the use of the internet to
increase the dissemination of empirically supported
psychological treatments to anyone in need [50]. Research has
shown promising and compelling evidence that
internet-delivered psychological interventions are effective for
a variety of psychosocial problems, including anxiety and
depressive disorders [51,52]. The main advantages of
internet-delivered treatments over traditional delivery methods
(eg, face-to-face therapy) include widespread access and
dissemination [53], a nonstigmatizing way of receiving
psychological treatment [54], and increased cost-effectiveness
[55].
Research has shown that transdiagnostic internet-delivered
treatments are more effective than control groups [29] and that
these treatments are at least as effective as individual and group
face-to-face transdiagnostic treatments [33]. However, most of
the existing literature on transdiagnostic treatments is limited
to studies conducted in community settings, with few studies
carried out in public contexts such as primary or specialized
care [21]. Indeed, to our knowledge, no transdiagnostic
internet-delivered treatments for anxiety and depression have
been conducted in specialized public mental health care. This
is somewhat surprising because transdiagnostic
internet-delivered treatments in this particular setting could
have several advantages for both clinicians and the patients
attending these centers. First, anxiety and depressive disorders
are disorders with the highest prevalence rates [2,3]. Second,
resources in these settings are usually scarce, which affects both
the quantity and the quality of the mental health care provided
[56]. Third, a large percentage of patients with anxiety and
depressive disorders do not receive treatment in mental health
care centers [57]. In the specific case of Spain, most patients
attending public mental health units suffer from anxiety and
depressive disorders [58], the ratio of clinical psychologists to
patients is one of the lowest in Europe [59], and patients have
to endure long waitlists to receive treatment [60]. Fourth,
transdiagnostic treatments can be provided at a lower cost (eg,
in terms of training) [61]. Finally, the use of the internet can
help improve mental health services, for instance, by reducing
the waiting period to receive face-to-face treatment [62] or by
implementing these treatments as part of a stepped-care model
that takes patients’ profiles and needs into account. Thus, each
patient can be assigned the most appropriate treatment [63],
leaving face-to-face therapy for those patients who are less
likely to benefit from internet-delivered interventions.
This Study
Taking all of this into consideration, in this study, an RCT was
conducted to test the effectiveness of a transdiagnostic
internet-delivered protocol for ED (EmotionRegulation),
compared with TAU provided in Spanish public specialized
mental health care. EmotionRegulation includes components
of the UP and the skills from DBT (eg, mindfulness what and
how techniques), and it was designed to target a wide range of
EDs, including major depressive disorder (MDD), dysthymic
disorder (DD), PD, AG, SAD, GAD, OCD, anxiety NOS, and
depression NOS. It was hypothesized that (1) the
EmotionRegulation group would outperform the TAU group
on measures of overall anxiety and depression, temperament
(ie, BI and BA), and health-related quality of life (QoL) at
posttreatment; (2) these posttreatment changes would be
maintained at follow-up; (3) a significantly greater clinical
change would be observed in EmotionRegulation compared
with TAU; and (4) participants in the EmotionRegulation group




A 2-armed RCT was conducted. Participants were randomly
assigned in a 1:1 ratio to one of the following 2 conditions: (1)
EmotionRegulation and (2) TAU. Participants were stratified
by principal diagnosis, performing block randomization in
blocks of 4 to ensure that all the principal diagnoses were
equally represented across conditions. Computer-generated
random number sequences were obtained using statistical
software (Epidat 4.1, SourceForge). This task was performed
by an independent researcher who was unaware of the
characteristics of the study.
The study was conducted in compliance with the study protocol,
the Consolidated Standards of Reporting Trials (CONSORT)
statement [64,65], the CONSORT of Electronic and Mobile
HEalth Applications and onLine TeleHealth guidelines [66],
and the Declaration of Helsinki and good clinical practice. A
full description of the study protocol has been reported
elsewhere [67]. The RCT obtained ethical approval from the
Ethics Committee of Universitat Jaume I (Castellón, Spain) and
the Clinical Research Ethics Committees of 3 hospitals
(Consorcio Hospitalario Provincial de Castellón, Hospital
Universitario de la Ribera, and Hospital Universitario Vall
d’Hebron). The study protocol was registered at
ClinicalTrials.gov (NCT02345668) on July 27, 2015. The
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duration of the intervention period was 18 weeks for participants
in both conditions, and participants’assessments were conducted
at pre- and posttreatment and at 3- and 12-month follow-ups.
Both the intervention (EmotionRegulation) and the assessment
instruments, except the diagnostic interview, were delivered
through a web platform designed by our research group [68].
All transferred data were secured via Advanced Encryption
Standard-256 encryption. Study researchers conducting
posttreatment and follow-up assessments (ie, diagnostic
interviews) were blinded to the participants’ treatment
conditions. To ensure blinding of the evaluators, participants
were informed that an independent researcher would contact
them to conduct follow-up assessments, and they were asked
not to disclose the treatment condition to which they had been
allocated. This study reports pre- to posttreatment data and data
at 3-month follow-up.
Sample Size
Several studies were considered for the calculation of the
expected sample size [23,69,70]. On the basis of a minimum
power of 0.80 in a 1-tailed test (ie, t test for differences between
2 independent means), an α of .05, and an estimated dropout
rate of approximately 30%, a sample size of 78 participants per
condition was determined to detect a posttreatment effect size
of 0.40 (Cohen d) between the 2 conditions. In addition, based
on the literature [71,72], an estimated dropout rate of
approximately 30% was expected. Thus, the final sample size
was set at 100 participants per condition (total of 200
participants). The G*Power software (version 3.1.9.4,
Heinrich-Heine-Universität) was used to calculate the sample
size [73].
Participants
Participants were recruited from adult outpatients attending
Spanish public specialized mental health care services (mental
health units) to seek psychological and/or psychiatric treatment
between July 2015 and June 2019. Initial recruitment was
performed by clinical psychologists and psychiatrists working
in these centers, and it took place in 3 different hospitals:
Consorcio Hospitalario Provincial de Castellón (Castellón de
la Plana), Hospital Universitario de la Ribera (Valencia), and
Hospital Universitario Vall d’Hebrón (Barcelona). Recruitment
was performed as follows: (1) once psychiatrists and clinical
psychologists had identified a potential candidate, they offered
the patient the possibility of participating in the study and
described the study characteristics to him or her; (2) patients
who were interested in participating gave their informed written
consent, and the clinician filled out a document with the
participants’ sociodemographic and clinical characteristics
(moreover, in this stage, participants were provided with a
document containing information about the study); (3) one of
the researchers involved in the study contacted the participants
by phone to schedule a face-to-face appointment to evaluate
eligibility criteria using a structured diagnostic interview; and
(4) whenever a participant met the eligibility criteria, an
independent researcher (unaware of the study characteristics)
was contacted to implement randomization, and participants
completed the remaining assessment instruments (self-reported
questionnaires) through web-based surveys.
Participants were selected based on the following inclusion
criteria: (1) aged 18 years or older; (2) ability to understand and
read Spanish; (3) having access to the internet at home and an
email address; (4) meeting Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition (DSM-IV) diagnostic
criteria [74] for ED (ie, MDD, DD, depression NOS, PD, AG,
SAD, GAD, anxiety NOS, and OCD); (5) providing written
informed consent; (6) not suffering from a severe mental
disorder (schizophrenia, bipolar disorder, and alcohol and/or
substance dependence disorder); (7) not presenting a high risk
of suicide; (8) not suffering from a disabling medical disease
that prevented the participant from carrying out the
psychological treatment; and (9) not receiving another
psychological treatment during the study (in the experimental
group). Pharmacological treatment was allowed, but participants
had to be taking the same dose during the 2 months before
enrolling in the study. In addition, participants in the
experimental group whose medication was increased or changed
during the study period were excluded from the trial (decreases
in pharmacological treatment were accepted). There was no
monetary compensation for participation in the study under any




Clinical diagnoses were obtained using the mini-international
neuropsychiatric interview (MINI) version 5.00 [75,76], a brief
structured diagnostic psychiatric interview for the assessment
of key DSM-IV and International Classification of Diseases,
10th Revision, diagnoses.
Principal Outcomes
Beck Depression Inventory, Second Edition
Beck depression inventory, second edition (BDI-II) [77,78], is
a self-report questionnaire with 21 items about the different
symptoms characterizing MDD, added together to obtain the
total score, which can be a maximum of 63 points. The
instrument has shown good internal consistency (α=.76-.95).
The Spanish version also showed high internal consistency
(α=.87) for both the general and clinical populations (α=.89).
Cronbach α for the BDI-II in this study was .90.
Beck Anxiety Inventory
The Beck anxiety inventory (BAI) [79,80] is a 21-item
self-report scale that assesses anxiety, with a maximum score
of 63 points. Each item has a 4-point severity scale (from not
at all to severely) that addresses symptoms experienced during
the previous week. Previous validation studies have shown an
internal consistency ranging from 0.85 to 0.94 as well as
convergent and divergent validity. The Spanish version of the
BAI has demonstrated high internal consistency (α=.93).
Cronbach α for the BAI in this study was .92.
Secondary Outcomes
Behavioral Inhibition Scale and Behavioral Activation Scale
The behavioral inhibition scale (BIS) and behavioral activation
scale (BAS) [81,82] contains 20 items rated from 1 to 4, with
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7 BIS subscale items that evaluate emotional responses of
individuals to impending negative events and 13 BAS items
that evaluate the behavioral and emotional responses of
individuals to potentially positive events. The BIS and BAS
have shown good reliability in individuals with EDs (α=.73-.92)
and good convergent and discriminant validity as indicators of
temperament. The internal consistency of the Spanish version
ranges between 0.65 and 0.82. Cronbach α for the BIS and BAS
subscales in this study were .61 and .80, respectively.
Quality of Life EuroQoL-5D-3L Questionnaire
Quality of life EuroQoL-5D-3L (EQ-5D-3L) questionnaire
[83,84] is a generic instrument that measures health-related QoL
and consists of 2 parts. Part 1 assesses self-reported problems
in each of the following 5 domains: mobility, self-care, daily
activities, pain/discomfort, and anxiety/depression. Each domain
is divided into 3 levels of severity corresponding to no problems,
some problems, and extreme problems, yielding a
population-based preference score or societal index (SI). A total
of 243 theoretically possible health states can be obtained, and
the SI is calculated on the basis of these health states. Values
range from 1 (best health state) to 0 (death). However, this index
may also provide negative values that correspond to health states
perceived as worse than death. Utility scores for these health
states were assigned using the available Spanish population
tariffs. Part 2 records the subjects’ self-assessed health on a
visual analog scale (VAS), a 10-cm vertical line on which the
best and worst imaginable health states score 100 and 0,
respectively. In this study, health-related QoL was assessed
using the VAS.
Disorder-Specific Measures
Disorder-specific symptoms were evaluated using 4 different
self-report questionnaires. Symptoms of GAD were assessed
using the Penn State Worry Questionnaire [85,86]. PD and AG
symptoms were evaluated using the Panic Disorder Severity
Scale, Self-Reported [87,88]. SAD symptoms were evaluated
using the Social Interaction Anxiety Scale [89,90], and OCD
symptoms were assessed using the Obsessive Compulsive
Inventory-Revised [91,92]. All 4 instruments have shown
adequate psychometric properties in both the original and
Spanish validations. Cronbach αs for these scales in this study
were .78, .89, .80, and .91, respectively. More details about
these assessment instruments have been described elsewhere
[67].
Treatment Acceptability
Expectations and Opinions of Treatment Scales
These questionnaires were adapted from the study by Borkovec
and Nau [93]. Each scale is made up of 5 items, rated from 0
(nothing at all) to 10 (completely), which ask how logical the
treatment seems to be (How logical do youthink this treatment
is?), to what extent it satisfies the patient (How satisfied are
you with the treatment?), whether the patient would recommend
it to a person with the same problem (To what extent do you
feel confident recommending this treatment to a friend who has
the same problems?), whether it could be used to treat other
psychological problems (To what extent do you think this
treatment could be useful in treating other psychological
problems?), and its usefulness for the patient’s problem (To
what extent do you think this treatment will be/was helpful to
you?). The expectation scale was applied after the treatment
rationale was explained. Its objective is to measure subjective
patient expectations regarding this treatment. The opinion scale
was administered when the patient had completed the treatment,
and it was designed to assess satisfaction with this treatment.
Treatments
EmotionRegulation
Following randomization, participants in the treatment condition
were contacted via telephone by a researcher who provided free
access to EmotionRegulation, a 12-module transdiagnostic
internet-delivered protocol for the treatment of ED, namely,
MDD, DD, depression NOS, PD, AG, GAD, SAD, anxiety
NOS, and OCD. The protocol is delivered through a web
platform [68] designed by our research group. Access to the
web platform is through a unique username-password
combination and is available 24 hours a day. The treatment was
first developed as a manualized transdiagnostic treatment
protocol with handbooks for both patient and therapist and then
adapted to be delivered through a web-based platform. The web
platform has successfully been used in previous RCTs exploring
the efficacy of internet-delivered treatments for several
disorders, such as depression [94] and flying phobia [95].
The main core components are based on the UP [35,36], but
the protocol also contains treatment strategies derived from
DBT [46]. The principal aim of the treatment components in
EmotionRegulation is to learn and practice adaptive ways to
regulate emotions from a transdiagnostic perspective, with the
following treatment components: present-focused emotional
awareness, cognitive flexibility, emotional avoidance and
emotion-driven behaviors, and exposure procedures
(interoceptive and situational). The protocol also contains a
module to facilitate the patient’s engagement with the therapy
(motivation for change), a module with psychoeducation about
emotions, and a relapse prevention module. Regarding the DBT
components, greater emphasis was placed on the present-focused
emotional awareness component by adapting and including
strategies such as the what and how techniques and the concept
of radical acceptance. Moreover, the opposite action was
integrated into the treatment as a way to address emotion-driven
behaviors. EmotionRegulation includes a Welcome module that
contains general information about the protocol and its goals
as well as recommendations for benefiting from it and 12
treatment modules (described in Table 1).
The modules are sequential to enable step-by-step movement
through the program. The program duration can vary among
the users, and participants had access to the protocol for a
maximum period of 18 weeks. Moreover, participants were
allowed to use the program any time they wanted during the
trial period (ie, during the follow-up periods).
Regarding guidance, all participants in this condition received
therapist and automated support. Therapist support consisted
of (1) an initial face-to-face session to explain the characteristics
of the study and administer the diagnostic interview to confirm
the eligibility criteria, (2) an initial phone call encouraging
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participants to start the intervention after the baseline
assessments had been completed, (3) 1 weekly brief phone call
(maximum of 10 min) during the treatment period, and (4) a
final phone call (once the treatment had ended) to remind
participants that they would be allowed to use the program at
any time during the trial period and that they would be contacted
for follow-up assessments. Automated support consisted of 2
weekly text messages reminding participants about the
importance of completing the homework tasks and encouraging
them to review the treatment modules. Text messages were sent
through a secure web platform [96]. This web platform was
only used to send text messages (unidirectionally) with
predefined contents, and they did not include personal
information that could have identified the participants.
Additional details about the treatment and support protocols,
as well as other functionalities of the web-based platform, have
been published elsewhere [67]. Finally, it is important to note
that all participants in this condition were allowed to continue
to receive TAU, but only for monitoring of pharmacological
treatment. Participants who received other forms of treatment
during the study period (eg, psychological treatment) or who
experienced increases or changes in pharmacological treatment
were excluded from the analyses.
Table 1. Treatment modules and their objectives.
ObjectiveModule
Provides a framework about the role of emotion regulation in EDa.1. Introduction to treatment
To analyze pros and cons of changing, emphasize the importance of being motivated, and help to establish
significant life goals.
2. Motivation for change and goal setting
Provides psychoeducation about the roles and functions of emotions and trains the patient to track the
3 components of emotional experiences.
3. Understanding the role of emotions
Aims to train the patient in nonjudgmental emotional awareness (ie, mindfulness what and how skills)
and the acceptance of emotional experiences.
4. Nonjudgmental emotional awareness and
acceptance of emotional experiences
To continue to practice the acceptance of emotional experiences and increase awareness of physical
sensations, thoughts, emotions, and daily activities.
5. Practicing present-focused awareness
Focuses on the identification of maladaptive ways of thinking (ie, thinking traps).6. Learning to be flexible
Aims to teach the patients strategies to modify thinking traps (ie, cognitive reappraisal). It also provides
information about intrusive thoughts and how to deal with them.
7. Practicing cognitive flexibility
Aims to teach the patients to identify the emotion avoidance strategies that contribute to the maintenance
of ED.
8. Emotional avoidance
To learn the concept of EDBsb and replace their maladaptive EDB with other more adaptive behaviors.9. Emotion-driven behaviors
To teach the role of physical sensations in the emotional response and provide training in interoceptive
exposure.
10. Accepting and facing physical sensa-
tions
To build exposure hierarchies to help the patients begin to face situation-elicited avoided emotions.11. Facing emotions in the contexts in
which they occur
To review what patients have learned throughout the program, schedule the future practice of the learned





TAU was treatment as delivered in current daily practice by
psychiatrists and clinical psychologists in the mental health
centers in Spain. TAU in this study was provided by 3 hospitals:
Consorcio Hospitalario Provincial de Castellón (Castellón de
la Plana), Hospital Universitario de la Ribera (Valencia), and
Hospital Universitario Vall d’Hebron (Barcelona). To maximize
the external validity of this RCT, participants in this condition
were allowed to receive either psychiatric treatment (ie,
prescription and monitoring of antidepressant and/or anxiolytic
medication), psychological treatment (including case
management, group psychotherapy, empathic listening, and/or
supportive counseling), or a combination of both. The frequency
of visits during the 18-week treatment period varied depending
on the type of treatment (ie, psychiatric or psychological)
provided to the participant. Patients in the TAU condition who
were already receiving any of the aforementioned treatments at
the time of enrollment were informed that they would continue
to receive these services during the treatment period.
Furthermore, participants receiving a treatment other than those
provided in the mental health unit were excluded from the trial.
All participants allocated to TAU were offered free access to
the treatment platform after the study ended.
Therapists and Treatment Fidelity
The treatment and support protocols were administered by
doctoral students with at least two years of experience in the
diagnosis, psychological assessment, and application of CBT
for different ED. Several steps were taken to ensure treatment
fidelity. First, therapists had previously been trained in the
application of the treatment modules. Second, a support protocol
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(ie, weekly phone calls and automated text messages) was
developed to be applied to all the participants in the
EmotionRegulation condition. This support protocol has been
briefly described earlier, but more details can be found in the
study by González-Robles et al [67]. Third, to increase diagnosis
reliability, all therapists involved in the participants’ assessment
were trained in the application of the diagnostic interview
(MINI).
Data Analysis Plan
All analyses were performed using the Statistical Package for
Social Sciences version 25.
First, chi-square tests for categorical data and independent
samples t tests for continuous data were performed to confirm
that there were no significant differences between the groups
at baseline on any of the sociodemographic and clinical
variables.
Intention-to-treat (ITT) analyses were performed following
Newman’s guidelines [97], using maximum likelihood (ML)
estimation through the expectation maximization imputation
method. To handle missing data, we followed the procedure
suggested by Hair et al [98]. First, we explored the types of
missing data and determined that data were missing at the
construct level. On the basis of this, we concluded that the data
were susceptible to imputation. Second, the quantity of missing
data was analyzed to ensure that none of the measures exceeded
the recommended limits to implement this method [99]. Third,
Little’s missing completely at random (MCAR) tests were
carried out to analyze the pattern of missing data, concluding
that all missing data were MCAR (X225=28.7; P=.28). Finally,
a sensitivity analysis was performed on the main outcomes to
compare the results of the per-protocol sample (ie, completers)
with the imputed values. This analysis revealed that the ML
estimation was not likely to produce biased estimations in the
main analyses, reaching the same conclusions in both the
completers and the imputed dataset (per-protocol: FBAI
(1,127)=6.1; P=.02; and FBDI (1,127)=15.54; P<.001; ITT: FBAI
(1,197)=4.79; P=.03; and FBDI (1,197)=12.97; P<.001).
To test the first hypothesis and control for baseline differences,
analyses of covariance (ANCOVAs) were performed to compare
the effects of the groups on measures of anxiety, depression,
temperament, and health-related QoL, taking condition as the
between-subject variable and the pretreatment scores as
covariates. The use of ANCOVAs for the analysis has been
recommended by several authors as a more powerful tool to
analyze data in studies with randomized designs [100,101].
To test the second hypothesis, a 2 (condition:
EmotionRegulation vs TAU) × 3 (time: pretreatment vs
posttreatment vs 3-month follow-up) mixed analysis of variance
(ANOVA) was performed to test whether the differences
between EmotionRegulation and TAU (ie, between-subjects
factors) were maintained at follow-up (ie, within-subject factor).
The following assumptions for the mixed ANOVA were
analyzed: normality (Shapiro-Wilk test), homoscedasticity
(Levene test), independence (nonparametric Runs test), and
sphericity (Mauchly test). The degrees of freedom were
corrected using Greenhouse-Geisser whenever the sphericity
assumption was violated. Moreover, pairwise
Bonferroni-corrected tests were used for posthoc comparisons.
To compute the magnitude of both within-group and
between-group changes, effect sizes (Cohen d) were calculated
by dividing the differences between means by the pooled SD.
Effect sizes were interpreted according to Cohen convention:
effect sizes of 0.20 are considered low, effect sizes of 0.50 are
considered medium, and effect sizes of 0.80 and above are
considered large [102].
To test the third hypothesis, we explored the clinical significance
of the changes achieved by the participants as well as potential
deterioration rates using Jacobson and Truax’s reliable change
index (RCI) [103] for the main outcome measures (BDI-II and
BAI) in the completer sample for posttreatment and follow-up
measurements. First, the cutoff points for the posttreatment and
follow-up scores were determined to be within the range of a
functional distribution. The RCI was then calculated to test the
clinically significant change, with an RCI of |1.96| or greater
(P<.05). Finally, both criteria were taken into account to classify
participants into the following 4 categories: (1) recovered: when
the change is significantly reliable (RCI≥|1.96|; P<.05) and the
posttreatment score is located within the range of the functional
distribution (mean [SD 2]), (2) improved: when the change is
significantly reliable but the posttreatment score is below the
functional level, (3) not changed: when the change is not
significantly reliable and the posttreatment score does not reach
the functional level, and (4) deteriorated: when the change is
significantly reliable but the posttreatment score is worse than
the pretreatment score.
Finally, to test the fourth hypothesis, the scores on expectations
and opinions were analyzed by calculating means and SDs for
each of the items on the expectation and opinion of treatment
scales. In addition, 1-way ANOVAs were performed to analyze
the significance of the differences between expectations and
opinions.
Results
Participant Flow and Attrition
A flowchart of the study participants is displayed in Figure 1.
A total of 326 patients expressed interest in the study, 281 of
whom were assessed for eligibility. Of these 281, 67 participants
were excluded from the study. A total of 214 participants were
randomized to either EmotionRegulation (n=106) or TAU
(n=108). In addition, 7 patients in each condition withdrew from
the study before the pretreatment assessment. Consequently,
these participants were not included in any of the analyses.
Regarding attrition, 35 participants in the EmotionRegulation
condition (35/106, 33.0%) and 34 in the TAU condition (34/108,
31.5%) dropped out of the study (reasons for dropout are shown
in Figure 1). In addition, 3 participants in the EmotionRegulation
condition had to be excluded from the trial because of a change
in their pharmacological treatment during the treatment period.
Posttreatment data were obtained from 63 participants (63/99,
64%) in the EmotionRegulation condition and from 67
participants (67/101, 66.3%) in the TAU condition. Follow-up
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data were collected from 51 participants (51/99, 52%) in the
EmotionRegulation condition and 56 participants (56/101,
55.4%) in the TAU condition. Finally, 99 participants in the
EmotionRegulation group and 101 participants in the TAU
condition were included in the ITT analysis.
Figure 1. Flowchart of participants. ED: emotional disorder; DSM-IV-TR; Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,
Text Revision; ITT: intention-to-treat.
Baseline Characteristics
Participants (N=200) had a mean age of 38.44 years (SD 10.80;
range 18-68), and they were mostly females (138/200, 69.0%).
Table 2 provides the sociodemographic and clinical
characteristics for both conditions at baseline. There were no
significant differences between the EmotionRegulation and
TAU groups at baseline on any of the sociodemographic and
clinical characteristics. Moreover, no significant differences
were found for medication, principal diagnosis, number of
comorbid diagnoses, or clinical severity on any of the measures.
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Table 2. Demographic and clinical characteristics of the sample at baseline (N=200).





.800.25 (198)N/Aa38.25 (11.03)38.64 (10.61)Age (years), mean (SD)
.26N/A1.3 (1)Sex, n (%)
66 (65.3)72 (72)Female
35 (34.7)27 (27)Male
.78N/A1.1 (3)Marital status, n (%)
26 (25.7)22 (22)Single
65 (64.4)63 (63)Married or partnered
10 (9.9)14 (14)Divorced or widowed
.35N/A2.1 (2)Education, n (%)
36 (35.6)26 (26)Basic studies
35 (34.7)41 (41)Secondary studies
30 (29.7)32 (32)University studies





17 (16.8)13 (13)Off work
6 (5.9)3 (3)Retired
.91N/A1.0 (4)Monthly income (€), n (%)
28 (27.7)27 (27)None
16 (15.8)20 (20)<641.40 (US $699.45)
38 (37.6)32 (32)641.40-1282.80 (US $699.46-
1398.89)
17 (16.8)18 (18)1282.81-2565.60 (US $1398.90-
2797.78)
2 (2.0)2 (2)>2565.60 (US $2798.78)
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8 (7.9)6 (6)≥ 3






bGAD: generalized anxiety disorder.
cAG: agoraphobia.
dPD: panic disorder.
eSAD: social anxiety disorder.
fOCD: obsessive compulsive disorder.
gMDD: major depressive disorder.
hDD: dysthymic disorder.
iNOS: not otherwise specified.
Amount of Support Provided
Participants in the EmotionRegulation condition were provided
a mean of 49.97 min (SD 41.20 min) of clinician support
delivered through phone calls. In addition, an initial face-to-face
session was scheduled with all the patients in both conditions
(EmotionRegulation and TAU) to explain the study and perform
the screening assessment, with an approximate duration of 60
min for each participant. Regarding automated support, that is,
weekly text messages, participants in the EmotionRegulation
group were sent a mean of 24.61 text messages (SD 8.80).
Effectiveness of EmotionRegulation on Primary and
Secondary Outcome Measures
Table 3 provides the means and SDs for the 2 conditions at pre-
and posttreatment and at 3-month follow-up on both primary
and secondary outcome measures. Additional data on change
scores and within-group effect sizes for diagnosis-specific
measures are reported in Multimedia Appendix 1.
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Table 3. Descriptive statistics for EmotionRegulation and treatment as usual at pretreatment, posttreatment, and 3-month follow-up.
Treatment as usual (n=101), mean (SD)EmotionRegulation (n=99), mean (SD)Instrument
F/UPost-TPre-TF/UcPost-TbPre-Ta
17.90 (13.23)19.85 (12.85)24.08 (11.69)15.70 (11.97)15.54 (10.9)23.49 (11.01)Beck depression inventory-II
18.11 (11.21)18.88 (11.31)22.27 (12.93)15.41 (10.50)15.08 (10.12)20.00 (11.88)Beck anxiety inventory
22.44 (2.42)22.87 (2.44)23.40 (2.87)21.81 (2.67)22.30 (2.67)23.32 (2.76)Behavioral inhibition and behav-
ioral activation scale—behav-
ioral inhibition system








Pretreatment to Posttreatment Effects
Principal Outcome Measures
The ANCOVAs of the baseline-corrected postintervention scores
revealed a significant condition effect on anxiety (BAI:
F1,197=4.79; P=.03; η
2 partial=0.02) and depression (BDI-II:
F1,197=12.97; P<.001; η
2 partial=0.06), reflecting that the
EmotionRegulation group showed significantly lower
posttreatment anxiety and depression scores than the TAU
group.
Secondary Outcome Measures
Regarding the measures of BI and BA (BISBAS), the
ANCOVAs yielded a significant condition effect for the BA
dimension (BAS: F1,197=9.66; P=.002; η
2 partial=0.05),
indicating that patients in the EmotionRegulation group had
significantly higher BA scores than those in the TAU group.
Although patients in the EmotionRegulation group showed
greater improvements in the BI dimension, no significant
differences between groups were observed for this dimension
(BIS: F1,197=2.44; P=.12; η
2 partial=0.01). On the other hand,
the ANCOVA revealed a significant condition effect on
health-related QoL (EQ-5D-3L: F1,197=10.38; P=.001; η
2
partial=0.05), indicating that health-related QoL scores were
significantly higher in the EmotionRegulation group
posttreatment than in the TAU group.
Follow-Up Effects
Principal Outcome Measures
For depression, a significant condition×time interaction effect
was found (F2,396=6.18; P=.01; η
2 partial=0.03). There was a
significant time effect (F2,396=102.07; P<.001; η
2 partial=0.34)
and a nonsignificant condition effect on anxiety scores
(F1,198=2.25; P=.14; η
2 partial=0.01). In the EmotionRegulation
condition, Bonferroni tests indicated that the differences between
pre- and posttreatment were significant (P<.001), but the
differences between posttreatment and follow-up were not
significant (P>.99), revealing that the reductions in depression
scores were maintained at the 3-month follow-up.
The analyses showed no condition×time interaction effect on
anxiety (F1.62,319.88=0.75; P=.45; η
2 partial=0.004). However,
there was a significant time effect (F1.62,319.88=29.35; P<.001;
η2 partial=0.13) and a significant condition effect on anxiety
scores (F1,198=4.20; P=.04; η
2 partial=0.02). Although there
was no interaction effect, we decided to perform posthoc tests
to preliminarily explore the direction of the changes. In the
EmotionRegulation group, posthoc comparison tests revealed
significant differences between pre- and posttreatment (P<.001),
but no significant differences between posttreatment and
follow-up in the EmotionRegulation group (P>.99).
Secondary Outcome Measures
Regarding temperament measures, no significant condition×time
interaction effect was found for the BIS subscale
(F1.49,295.29=0.93; P=.34; η
2 partial=0.005). A significant time
effect was found (F1.49,295.29=15.33; P<.001; η
2 partial=0.07),
but the effect of condition was not significant (F1,198=2.51;
P=.12; η2 partial=0.01).
For the BAS subscale, a significant condition×effect interaction
effect was found (F1.84,363.40=5.62; P=.02; η
2 partial=0.03). In
the EmotionRegulation group, posthoc tests showed that BAS
scores were significantly higher at posttreatment than at baseline
(P=.05). However, these differences vanished at follow-up, as
shown by the comparison between pretreatment and follow-up
scores (P>.99).
Regarding health-related QoL, the analyses did not reveal a
condition×time interaction effect (F1.7,336.93=2.73; P=.08;
η2partial=0.01). However, there was a significant time effect
(F2,396=23.34; P=.001; η
2 partial=0.11) and a significant
condition effect (F1,198=6.3; P=.01; η
2 partial=0.03), which
indicated a significant improvement in health-related QoL at
posttreatment in both EmotionRegulation and TAU and
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generally higher health-related QoL in the EmotionRegulation
group. Table 4 provides the effect sizes for the within- and
between-group comparisons.
Table 4. Within- and between-group effect sizes and 95% CIs.
EmotionRegulation versus TAU, d (95%
CI)




















0.41 (0.25 to 0.57)Beck anxiety inventory
0.25 (−0.03 to
0.52)




































aTAU: treatment as usual.
bF/U: 3-month follow-up.
cPositive effect sizes denote a decrease in scores, whereas negative effect sizes denote an increase.
Significance of Clinical Improvements
The results for the significance of the clinical changes on
measures of overall depression and anxiety (BDI-II and BAI,
respectively) are summarized below.
Changes in Depression
Baseline to Posttreatment Changes
In the EmotionRegulation group, 84% (85/99) of the patients
achieved a functional change in their depression scores, whereas
only 58.4% (59/101) did so in the TAU group, and these
differences were significant (X21=10.5; P=.001). In the
EmotionRegulation group, 59% (58/99) of participants
recovered, 25% (25/99) improved, 10% (10/99) did not change,
and 6% (6/99) deteriorated; whereas in the TAU group, 38.6%
(39/101) of participants recovered, 18.8% (19/101) improved,
32.7% (33/101) did not change, and 8.9% (9/101) deteriorated
(Figure 2). Differences betweeen groups were significant
(X23=11.7; P=.009).
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Figure 2. Percentages of participants recovered, improved, did not change, and deteriorated on depression scores (Beck depression inventory-II) in
EmotionRegulation (outer circle) and treatment as usual (inner circle). F/U: follow-up.
Baseline to Follow-Up Changes
In the EmotionRegulation group, 80% (79/99) of the patients
achieved a functional change in their depression scores, whereas
only 70.3% (71/101) of the patients did so in the TAU group,
and these differences were not significant (X21=1.6; P=.20). In
the EmotionRegulation group, 65% (64/99) of participants
recovered, 16% (16/99) improved, 16% (16/99) did not change,
and 4% (4/99) deteriorated; whereas in the TAU group, 50.5%
(51/101) of participants recovered, 19.8% (20/101) improved,
17.8% (18/101) did not change, and 12.9% (13/101) had
deteriorated (Figure 2). No significant differences betweeen
groups were found (X23=3.7; P=.30).
Changes in Anxiety
Baseline to Posttreatment Changes
There were no significant differences in the proportion of
patients who achieved a functional change in their anxiety scores
between the 2 conditions (X21=1.2; P=.28). However, 73%
(72/99) of participants in the EmotionRegulation group achieved
a functional change in anxiety and 64.4% (65/101) did so in the
TAU group. . In the EmotionRegulation group, 56% (55/99) of
participants recovered, 18% (18/99) improved, 21% (21/99) did
not change, and 6% (6/99) deteriorated. In contrast, in the TAU
group, 36.6% (37/101) of participants were recovered, 26.7%
(27/101) were improved, 17.8% (18/101) did not change, and
17.8% (18/101) had deteriorated (Figure 3). Differences
betweeen groups were marginally significant (X23=7.3; P=.06).
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Figure 3. Percentages of participants recovered, improved, did not change, and deteriorated on anxiety scores (Beck anxiety inventory) in
EmotionRegulation (outer circle) and treatment as usual (inner circle). F/U: follow-up.
Baseline to Follow-Up Changes
There were no significant differences in the proportion of
patients who achieved a functional change in their anxiety scores
between the 2 conditions (X21=0.9; P=.34). In the
EmotionRegulation group, 49% (49/99) of participants
recovered, 14% (14/99) improved, 28% (28/99) did not change,
and 10% (10/99) deteriorated. In contrast, in the TAU group,
47.5% (48/101) of participants were recovered, 22.8% (23/101)
were improved, 8.9% (9/101) did not change, and 19.8%
(20/101) had deteriorated (Figure 3). Differences betweeen
groups were significant (X23=8.2; P=.04).
Treatment Acceptability
Table 5 provides the means and SDs for expectations and
opinions about treatment in the completer sample of the
EmotionRegulation condition (n=63). As hypothesized, the
results indicate that participants reported high scores on all the
items measuring treatment expectations (scores between 7.56
and 7.81): logic of the treatment, satisfaction with the treatment,
recommending the treatment to other people with similar
problems, usefulness of the treatment for other psychological
problems, and usefulness of the treatment for one’s specific
problem. After receiving the intervention, scores for treatment
opinions were generally higher than scores for treatment
expectations (scores between 7.67 and 8.24).
A 1-way repeated measures ANOVA showed that, compared
with treatment expectations, the opinion of treatment was
significantly better for item 1 (logic of the treatment; F1,62=7.81;
P=.007; η2 partial=0.11), item 3 (recommending the treatment
to other people with similar problems; F1,62=4.80; P=.03; η
2
partial=0.07), and item 4 (usefulness of the treatment for other
psychological problems; F1,62=4.92; P=.30; η
2 partial=0.07).
No significant differences were found for item 2 (satisfaction
with the treatment; F1,62=3.05; P=.09; η
2 partial=0.05) or item
5 (usefulness of the treatment for one’s specific problem;
F1,62=.21; P=.65; η
2partial=0.003).
Table 5. Means and SDs for expectations and opinions of treatment (n=63).
Opinion, mean (SD)Expectations, mean (SD)Item
8.19 (1.62)7.65 (1.88)Treatment is logical
7.90 (1.71)7.56 (1.81)Satisfaction with the treatment
8.24 (1.85)7.81 (1.91)Recommend to others
8.05 (1.65)7.64 (1.86)Usefulness for other psychological problems
7.67 (2.13)7.76 (1.83)Usefulness for one’s specific problems
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The objective of this RCT was to explore whether a
transdiagnostic internet-delivered protocol (EmotionRegulation)
could be effective in treating a wide range of anxiety and
depressive disorders, compared with TAU as provided in
Spanish public specialized mental health care services. The
effectiveness of EmotionRegulation was evaluated on measures
of overall anxiety and depression, temperament (ie, BI and BA),
and health-related QoL. Finally, expectations and opinions were
evaluated to examine the acceptability of EmotionRegulation
for the patients. To our knowledge, this is the first RCT to report
data on a transdiagnostic internet-delivered protocol for ED in
public specialized mental health care.
Regarding our first hypothesis, the ANCOVAs revealed that
participants in the intervention group (EmotionRegulation)
improved their depression and anxiety symptoms at
posttreatment to a greater degree than participants in the TAU
group. Regarding the magnitude of the changes at posttreatment,
the analyses showed small but significant between-group effect
sizes for both depression and anxiety. With regard to measures
of temperament, the findings were mixed. Overall, although
patients in the EmotionRegulation group showed better scores
on the 2 subscales of the BIS and BAS than the TAU group,
only the differences on the BAS subscale were significant,
favoring the EmotionRegulation group. These results suggest
that the intervention tested in this study was able to modify
temperament, in line with a mechanistically transdiagnostic
approach that assumes the existence of underlying mechanisms
that account for the occurrence of specific symptoms. To our
knowledge, only 1 study has previously investigated the effect
of a mechanistically transdiagnostic treatment on the dimensions
of BI and BA [42]. Similar to the results obtained in our study,
in the study by Carl et al [42], both BI and BA improved
following treatment with the UP compared with a waitlist control
group, with small between-group effect sizes found for both the
BIS and BAS temperament dimensions. Moreover, these authors
showed associations between the gains in temperament
dimensions and symptoms of anxiety and depression,
particularly for BI, because lower BI scores were associated
with greater improvements in anxiety and depressive symptoms.
However, a limitation of this study was that the sample size was
small, and so the findings were preliminary. Thus, future RCTs
of mechanistically transdiagnostic treatments should analyze
the extent to which these interventions are able to modify BI
and BA and other related temperament dimensions such as
negative and positive affect to shed more light on this question
[104,105]. Finally, as hypothesized, EmotionRegulation was
superior to TAU in improving health-related QoL, with a small
but significant between-group effect size observed for the
EQ-5D-3L scale. In this regard, it is known that pharmacological
treatment could be linked to some variables associated with
health-related QoL, such as fatigue and sexual functioning [106].
Therefore, decreases in medication may have indirectly
influenced the QoL in some patients. However, these decreases
were not measured, and hence, no analyses could be performed
to analyze this aspect.
Furthermore, to evaluate the significance of the clinical gains,
Jacobson and Truax’s RCI was obtained for the principal
outcome measures, that is, BDI-II and BAI.
Consistent with the aforementioned results, significant
differences were observed in the proportion of patients who
achieved a functional change in depression scores, with a
significantly higher number of patients within the functional
range in the EmotionRegulation condition (85/99, 84%) than
in the TAU group (59/101, 58.4%). Regarding anxiety scores,
although no significant differences were observed between the
2 groups in the proportion of patients reaching a functional
change, a higher proportion of patients in the EmotionRegulation
group (72/99, 73%) than those in the TAU group (65/101,
64.4%) reached a functional change. Furthermore, significant
differences were found in the proportion of patients recovered,
improved, did not change, and deteriorated, with better general
results for the intervention group than for the TAU group. At
follow-up, there were no differences in the proportion of patients
reaching a functional change in either depression or anxiety.
Therefore, it can be concluded that these differences tended to
diminish between groups at follow-up.
Regarding the acceptability of EmotionRegulation, expectations
about the treatment were high (scores ≥7). After receiving the
treatment, compared with expectations, the participants rated
the program as significantly more logical, more recommendable
for other people with similar problems and more useful for the
treatment of other psychological problems. The study of
acceptability is important because expectations about treatment
have been shown to affect treatment outcomes [107].
Furthermore, because most transdiagnostic internet-delivered
protocols have been conducted in community samples [108], it
is necessary to continue to explore the acceptability of these
interventions in specialized care.
Overall, the findings showed that the transdiagnostic
internet-delivered protocol tested in this RCT was more effective
than TAU for the treatment of anxiety and depressive disorders
in public specialized mental health care. On the one hand, the
results show that EmotionRegulation led to greater
improvements at posttreatment, and these gains were maintained
at follow-up. Regarding TAU, the results reveal that patients
undergoing TAU also experienced improvement over time, but
it was slower and less pronounced than in patients receiving
EmotionRegulation. The generally lower intensity of TAU (ie,
lower frequency of therapy sessions) and the fact that for most
patients TAU was limited to pharmacotherapy (with no access
to psychological treatment) might partly account for these
results. On the other hand, as anticipated, and in line with
previous studies conducted by our research group using the
same treatment platform [94,109], scores on expectations and
opinions demonstrated EmotionRegulation’s acceptability for
participants.
The results obtained in this RCT have implications for both
research and clinical practice, especially in the context of public
specialized mental health care. First, the findings obtained in
this study support the effectiveness of a mechanistically
transdiagnostic internet-delivered protocol for the treatment of
EDs, and they contribute to the literature in this particular field
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[23,27,36,110-112]. Specifically, a combination of the
components of the UP and DBT regulation skills was found to
be more effective than TAU in treating ED. Second, as far as
we know, this is the first study to explore a transdiagnostic
internet-delivered treatment in public specialized mental health
care. As mentioned earlier, most research on transdiagnostic
web-based treatments has been conducted in community
settings, with a few of these studies carried out in primary care
[108]. The results showed that the intervention was found to be
more effective than TAU on the measures of generic depression,
anxiety, and QoL. These results are consistent with the literature
showing the superiority of CBT over TAU. For instance, a
meta-analysis showed that CBT outweighed TAU, with effect
sizes in the medium range on measures of generic anxiety
(Hedges g=0.70) and depression (Hedges g=0.69) [70]. As
surprising as these data might seem, the truth is that current
public mental health services still have to deal with a number
of barriers that hinder appropriate care delivery, such as
excessive waiting times to access mental health care [60], low
frequency of sessions [113], or inadequate follow-up care [56].
Moreover, the lack of training in evidence-based treatments
among professionals further adds to this problem [114]. Finally,
in Spain, several RCTs have been conducted using the internet
to provide evidence-based treatments, showing that they are
effective for the treatment of ED and, in particular, depression,
in community samples [94] and primary care [115,116], and
others are underway [117]. This study demonstrated that an
internet-delivered protocol for ED was effective in public
specialized care, a setting with a high demand, but much less
explored, thus adding to the literature on these treatments for
ED. Furthermore, the use of TAU as the control condition may
help to answer the question of “whether a new treatment or an
evidence-based psychotherapy really surpasses in outcome
effects what is ordinarily done at a given clinic” [118], thus
helping to make clinicians, researchers, and policy makers aware
of the limitations and aspects that should be improved in this
specific setting.
Limitations
Although the results of this RCT are promising, they should be
interpreted in light of the following limitations. First, although
several measures were taken to minimize attrition (eg, guidance
was provided to all the patients participating in
EmotionRegulation), the number of patients who dropped out
of the study was high (around 35%). However, this proportion
was close to what is typically observed in the literature on
internet-delivered psychological treatments (ie, approximately
30%-35%) [71]. Moreover, attrition in the TAU condition was
similar (34/108, 31.5%). Second, this RCT was not powered to
detect differences in disorder-specific measures (ie, for GAD,
PD or AG, SAD, and OCD). Therefore, future studies that meet
the minimum levels of statistical power to detect differences in
these measures are warranted. Third, although the frequency of
the session in TAU was low and most patients in this condition
were receiving only pharmacotherapy (as observed by the
researchers), these data were not monitored during the trial.
Finally, the results for acceptability (ie, expectations and
opinions) might not be entirely representative because data from
patients who dropped out of the intervention were not included
in these analyses.
Conclusions and Future Directions
The effectiveness of a mechanistically transdiagnostic
internet-delivered protocol for ED was compared with TAU in
public specialized mental health care. Although the results are
promising, more research in specialized care should be
conducted to extend the findings obtained in this study. First,
research on predictors and moderators of treatment outcomes
and dropout in this specific setting can help to delineate the
profiles of participants who are more likely to benefit from these
treatments and help to answer the classic question, “what
treatment, by whom, is most effective for this individual with
that specific problem, under which set of circumstances?” [119].
Moreover, we believe that the integration of principles from
different evidence-based protocols (eg, components of the UP
and DBT) can be a powerful strategy that should guide future
research on evidence-based psychotherapy. This strategy is in
line with process-based CBT and the new foundational question
proposed by Hofmann and Hayes [49] ( ie, “What core
biopsychosocial processes should be targeted with this client
given this goal in this situation, and how can they most
efficiently and effectively be changed?”) . Second, despite the
huge advances experienced by the field of internet-delivered
treatments in the past two decades, high dropout rates remain
a major challenge in the field. To continue to improve current
and future internet-delivered interventions, future studies should
strive to include dropouts in the analysis of acceptability using
both qualitative and quantitative approaches. Moreover, to
ensure the integrity, quality, and replicability of these studies,
adherence to existing research guidelines is of paramount
importance in this endeavor. Third, although we did not assess
the acceptability of clinicians involved in the RCT (ie,
psychiatrists, clinical psychologists, and nurses), it is worth
mentioning that some of them refused to participate in the
recruitment process, which might reflect negative attitudes
toward internet-delivered interventions among these
professionals. In this scenario, research efforts should be made
to inform clinicians and state holders about the benefits of
internet-delivered treatments, especially because they are seen
as authority figures and, therefore, their attitudes can have a
major impact on patients’ perceptions. Finally, although the
need for efficacy studies is out of doubt, we believe that it is of
paramount importance to conduct more implementation research
[120]. These studies may provide a much deeper understanding
of implementation variables that can either facilitate or hamper
the effective uptake of evidence-based protocols in real clinical
practice, such as the attitudes of clinicians and other
professionals toward internet-delivered treatments, or
economical and logistic aspects that are difficult to implement.
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ANCOVA: analysis of covariance
ANOVA: analysis of variance
BA: behavioral activation
BAI: Beck Anxiety Inventory
BAS: behavioral activation scale
BDI-II: Beck depression inventory, 2nd edition
BI: behavioral inhibition
BIS: behavioral inhibition scale
CBT: cognitive behavioral therapy
CONSORT: Consolidated Standards of Reporting Trials
DBT: dialectical behavioral therapy
DD: dysthymic disorder
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
ED: emotional disorder
EQ-5D-3L: EuroQoL-5D-3L questionnaire
GAD: generalized anxiety disorder
ITT: intention-to-treat
MCAR: missing completely at random
MDD: major depressive disorder
MINI: mini-international neuropsychiatric interview
ML: maximum likelihood
NOS: not otherwise specified
OCD: obsessive compulsive disorder
PD: panic disorder
QoL: quality of life
RCI: reliable change index
RCT: randomized controlled trial
SAD: social anxiety disorder
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TAU: treatment as usual
UP: Unified Protocol
VAS: visual analog scale
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